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Abstract 
Purpose: To evaluate the antibacterial activity and cytotoxic effects of Streptomyces sp. SRF1 culture 
filtrate extract against breast cancer cell line.  
Methods: The activity of the extract against Gram-positive and Gram-negative bacteria was initially 
screened by an agar-well diffusion method. Minimum inhibitory concentration (MIC) and minimum 
bactericidal concentration (MBC) values were measured by broth microdilution method. Time-kill assays 
were also performed, and extract-induced morphological and ultrastructural changes to bacterial cells 
were investigated. Sulforhodamine B (SRB) assay was performed to determine the cytotoxicity of the 
extract against the human breast cancer cell line, MCF-7. 
Results: Antibacterial activity by the extract was detected against four strains of Gram-positive 
pathogens including one strain of methicillin-susceptible Staphylococcus aureus (MSSA) and 3 strains 
of methicillin-resistant Staphylococcus aureus (MRSA) - with low MIC and MBC values. This activity 
was bactericidal after 6 h exposure. Morphological alterations were detected on the cell surface of both 
MSSA and MRSA. The extract also inhibited MCF-7 cell growth with half-maximal concentration (IC50) 
of 211.67 ± 33.95 µg/mL in 72 h. 
Conclusions: Streptomyces sp. SRF1 culture filtrate extract exhibits potent antibacterial and anticancer 
activities and thus, represents a potential source of antibacterial and anticancer drugs.  
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Soil microorganisms are an interesting source of 
new bioactive compounds. Compounds 
produced by such organisms can be developed 
and used in both agriculture and medicine [1-2]. 
Actinomycetes are soil bacteria known to 
produce various novel bioactive compounds. 
They are present in nature in a wide range of 
habitats, exhibit considerable species diversity, 
and considerable diversity in terms of their 
morphology, physiology, and biochemical 
activities [3]. Bioactive compounds produced by 
actinomycetes can potentially be developed as 
novel therapeutic agents.  
 
It was recently reported that 70 % of all 
antibiotics in use were derived from 
actinomycetes bacteria [2], 75 % of these from 
the genus Streptomyces [4-6]. Antibiotics derived 
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from Streptomyces have antibacterial, antifungal, 
antioxidant, and antitumor activities [7-11]. For 
example, Lee et al [12] reported that the soil 
Streptomyces sp. AMLK-135 had activity against 
methicillin-resistant Staphylococcus aureus 
(MRSA). The mangrove soil Streptomyces 
pluripotens MUSC 137 is reported to have 
cytotoxic activity against human cancer cell lines 
[11]. Ethyl acetate extract from rock soil 
Streptomyces spp. ERI-3 has been shown to 
inhibit the growth of Staphylococcus aureus, S. 
epidermidis and Candida albicans [7]. Moreover, 
other soil Streptomyces spp. such as S. 
antibioticus, S. flaveolus and S. psammoticus 
have been shown to inhibit MRSA [13]. 
 
Previous studies in our laboratory have shown 
that Streptomyces sp. SRF1, an isolate from rice 
field soil in northeast Thailand, has in vitro 
antifungal activity against some economically 
important plant pathogens [14]. Crude mycelial 
and culture filtrate extracts of isolate SRF1 also 
inhibit growth of the foodborne pathogen Bacillus 
cereus, inducing its cells to become elongated 
and abnormal in shape, and to lyse [15]. 
However, no information is available on the 
activity of isolate SRF1 against other medically 
important pathogens or against human cancer 
cell lines. The aim of the present study, 
therefore, was to elucidate the effects of isolate 
SRF1 culture filtrate extract against human 
pathogenic bacteria by agar well diffusion, by the 
microdilution and time-kill methods, and by 
scanning electron microscopy (SEM). Cytotoxic 
activity of the extract was also investigated 
against human breast cancer cell line MCF-7 in 




Preparation of culture filtrate extract 
 
Seven–day old mycelial discs of Streptomyces 
sp. isolate SRF 1 on half PDA were cut and 
placed into 50 mL of Arginine glycerol mineral 
salt (AGMS) medium before being incubated at 
37 ˚C with shaking at 250 rpm. After 14 days, the 
culture filtrate was collected and filtered through 
Whatman filter paper no. 1 before extraction with 
ethyl acetate by a liquid-liquid extraction method. 
The collected ethyl acetate layer was then 
evaporated under reduced pressure. The 50 mg 
of yellow brown gum extract obtained was then 
re-suspended in 0.1 mL of methanol and 
adjusted to 50 mg/mL final concentration using 
distilled water, before being tested for activity 
against 16 pathogenic bacteria (Table 1) and the 
MCF-7 breast cancer cell line. 
 
Preliminary screening for antibacterial 
activity  
 
The activity of the culture filtrate extract was 
preliminary screened against 16 pathogenic 
bacteria by agar well diffusion method as 
described by Sangdee et al [16]. In brief, the 16 
bacterial strains were cultured in 5 mL Mueller 
Hinton broth (MHB) and then they were 
incubated at 37 °C with shaking at 250 rpm for 3 
h. These were then adjusted to the 0.5 
McFarland standard before being swabbed to the 
surface of Mueller Hinton agar (MHA). Next, 
wells were cut using a sterile cork borer, and 0.1 
mL of culture filtrate extract was added to each 
well (final concentration of 50 mg/mL per well). 
After 16 – 18 h incubation (37 °C), the inhibition 
zones in each plate were measured. The 
antibiotics tetracycline and ciprofloxacin were 
used as reference standards at concentrations of 
250 μg/mL. 
 
Determination of minimum inhibitory concen-
tration (MIC) and minimum bactericidal 
concentration (MBC) 
 
Next, the antibacterial activity of the culture 
filtrate was determined quantitatively. Because 
zones of inhibition were only detected against 
Staphylococcus aureus (MSSA) DMST 2933, 
MRSA DMST 4738, MRSA DMST 20651 and 
MRSA DMST 20654, MIC and MBC assays were 
only performed with these strains. MIC and MBC 
values of the extracts were determined using the 
microdilution method. Briefly, a -3 - h culture of 
test bacteria was adjusted to 4 × 106 – 5 × 106) 
CFU/mL, and 10 μL aliquots of this were added 
to the wells of a 96 - well polystyrene tray. Ninety 
microliter volumes of a diluted culture filtrate 
extract (25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39, 
0.195 and 0.09 mg/mL) in MHB were then 
added. A growth control well, and an 
uninoculated control well were included in each 
plate. Tetracycline at a concentration of 250 
μg/mL was used as a positive control. Wells with 
the lowest concentration of extract that remained 
clear after incubation were recorded as the MIC. 
MBC values were determined by identifying the 
lowest concentration of extract capable of killing 




The bactericidal or bacteriostatic activity of the 
culture filtrate extract against MRSA DMST 
20651 and MSSA DMST 2933 were performed 
by time – kill assays using a method modified 
from Thammawat et al [17]. Briefly, bacterial 
cultures in mid - logarithmic growth phase were 
standardized to the 0.5 McFarland standard and 
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then they were inoculated into several tubes of 
MHB containing an equal volume of various 
concentrations of extract (0.78, 0.39 and 0.195 
mg/mL) so as to give final concentrations of 0.39 
mg/mL (2x MIC), 0.195 mg/mL (1x MIC), and 
0.09 mg/mL (0.5x MIC) extract, respectively. Test 
tubes of MHB without extract and MHB with 1x 
MIC tetracycline were included in each 
experiment. The final bacterial cell density was 
approximately 4 – 5 x 105 CFU/mL. All tubes 
were incubated at 37 °C. At 0, 2, 4, 6 and 24 h, 
time intervals, a small volume of bacterial 
suspension was removed, diluted, and spread 
onto the surface of MHA plates so that viable 
counts could be performed. The number of 
bacteria remaining in each sample was then 
plotted over time to determine the rate of killing. 
A three log10 reduction in bacterial numbers was 
considered to indicate bactericidal activity.  
 
Investigation of the effect of culture filtrate 
extract on bacterial cell morphology 
 
The effects of the culture filtrate extract on the 
surface characteristics and shape of MRSA 
DMST 20651 and MSSA DMST 2933 were 
investigated using a scanning electron 
microscope. Bacterial cells were incubated at 37 
°C for 12 h with shaking at 250 rpm, then 
harvested, resuspended in 0.5 mL MHB, and 
inoculated into 0.5 mL of 1 x MIC levels of the 
test extract. Samples were incubated at 37 °C for 
6 h with shaking at 250 rpm. Next, the bacterial 
cell pellets were collected and washed twice with 
1 mL phosphate - buffered saline (PBS) before 
being fixed with 2.5 % glutaraldehyde in 5 % 
sucrose overnight at 4 °C. Next, each cell pellet 
was dehydrated in an alcohol series. A total 
volume of 15 L of each sample was then 
applied to membranes. Dried samples were 
sputter - coated with gold and examined. 
 
Evaluation of anti-breast cancer cell line 
activity 
 
The anti-breast cancer cell line MCF-7 activity of 
the culture filtrate extract was elucidated using a 
SRB assay using a method modified from 
Buranrat et al [18] and Sangdee et al [19]. 
Briefly, MCF-7 cells were cultured in a 96 - well 
plate for 24 h. After that, the cells were exposed 
to the culture filtrate extract at concentrations of 
1 to 500 g/mL for 24 - 72 h. Next, the culture 
medium was removed before being fixed with 10 
% cold trichloroacetic acid for 1 h at 4 °C. Then, 
the plates were washed five times with deionized 
water, air – dried, and 0.4 % SRB in 1 % acetic 
acid was added for 30 min at room temperature. 
Next, the plates were washed three times with-1 
% acetic acid to remove any excess dye. After 
that, 200 µL of 10 mM Tris-base solution was 
added to solubilize the SRB dye within the cells. 
Next, the absorbance was measured at 540 nm 




The data were analyzed using t-test. Significant 
differences between treatments and control 
group were considered significant at p < 0.05. 
Statistical analyses was performed using SPSS 





Antibacterial activity of culture filtrate extract 
 
The activity of Streptomyces sp. SRF1 culture 
filtrate extract was investigated against 16 strains 
of human pathogenic bacteria. The extract 
inhibited the growth of 4 strains of Gram positive 
staphylococci, with large inhibition zone 
diameters compared to the control antibiotics 
tetracycline and ciprofloxacin. None of the test 
strains of Gram negative bacteria were affected 
(Table 1). Interestingly, MRSA DMST 20651 was 
resistant to ciprofloxacin and tetracycline at the 
tested concentration, but sensitive to the culture 
filtrate extract. MRSA DMST 20654 was also 
resistant to ciprofloxacin, but sensitive to the 
extract. Based on these results, only the 4 
sensitive staphylococcal strains were selected for 
further antibacterial testing. 
 
Minimum inhibitory concentration (MIC) and 
minimum bactericidal concentration (MBC) 
 
The MICs and MBCs of the extract were 
determined by a broth microdilution method. The 
results show that the MICs and MBCs of the 
extract were quite low. MIC and MBC values of 
0.195 and 0.390 mg/mL, respectively, were 
determined for all four test strains, MSSA DMST 
2933, MRSA DMST 4738, MRSA DMST 20651, 




Time-kill assays were performed to determine if 
the activity of Streptomyces sp. SRF1 culture 
filtrate extract is bacteriostatic or bactericidal. 
Bactericidal activity was defined as a ≥ 3 log10 
decrease in CFU/mL of the bacterial population 
compared with the untreated control, while 
bacteriostatic activity was defined as a  3 log10 
decrease in CFU/mL. The time kill profiles
Sangdee et al 
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Table 1: Activity of Streptomyces sp. SRF1 culture filtrate extract against 16 strains of bacterial pathogen using 
the antibiotics ciprofloxacin and tetracycline as reference standards 
 
Test bacterium 














S. aureus (MSSA) DMST 2933 36x36 25x25 32x32 0.195 0.390 
S. aureus (MRSA) DMST 20651 37x37 0 0 0.195 0.390 
MRSA DMST 4738 35x35 26x26 33x33 0.195 0.390 
MRSA DMST 20654 31x31 0 22x22 0.195 0.390 
V. cholerae (O1) DMST 9700 0 38x38 30x30 ND ND 
E. coli (EIEC) DMST 30545 0 20x20 0 ND ND 
E. coli O157:H7 DMST 12743 0 30x30 22x22 ND ND 
Sh. flexneri DMST 4423 0 33x33 0 ND ND 
Sh. flexneri DMST 17569 0 35x35 0 ND ND 
S. Typhi DMST 22842 0 33x33 0 ND ND 
S. Typhi DMST 16122 0 34x34 28x28 ND ND 
Sh. dysenteriae DMST 15110 0 33x33 20x20 ND ND 
S. Typhimurium ATCC 14028 0 31x31 26x26 ND ND 
Ps. aeruginosa ATCC 27853 0 25x25 0 ND ND 
Ps. aeruginosa 0 25x25 0 ND ND 
K. pneumonia 0 30x30 25x25 ND ND 
MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration; ND, not determined 
 
 
Figure 1: In vitro bactericidal activity of Streptomyces 
sp. SRF1 culture filtrate extract against MRSA DMST 
20651 (A) and MSSA DMST 2933 (B) at 
concentrations of 0.09 mg/mL (0.5 x MIC), 0.195 
mg/mL (1 x MIC), and 0.39 mg/mL (2 x MIC) 
compared to an untreated control and tetracycline 
(0.195 mg/mL).  : untreated control;  : 0.5 x MIC;  
▲: 1 x MIC;  × : 2 x MIC;  : tetracycline 
showed that the culture filtrate extract and 
standard tetracycline antibiotic were bactericidal 
against both MSSA DMST 2933 and MRSA 
DMST 20651. At 0.5 x MIC (0.09 mg/mL), the 
extract was able to reduce viable cell counts of 
both S. aureus strains by more than 3 log10 
during within 6 h. At concentrations of 1 x MIC 
(0.195 mg/mL) and 2 x MIC (0.39 mg/mL) also 
resulted in bactericidal activity against both S. 
aureus strains by 6 h, with lower viable cell 
counts than at 0.5 x MIC.  After 24 h incubation 
with 1 x MIC (0.195 mg/mL) and 2 x MIC (0.39 
mg/mL) levels of the extract, some of the treated 
bacteria remained viable but a 10 log10 CFU/mL 
reduction in viability of both MSSA and MRSA 
had occurred (Figure 1). These results indicate 
that the extract exhibited concentration- and 




The effect of Streptomyces sp. SRF1 culture 
filtrate extract on the morphology of MSSA 
DMST 2933 and MRSA DMST 20651 cells was 
investigated by SEM. Treatment of S. aureus 
with 1 x MIC levels of extract (0.195 mg/mL) 
induced morphological alterations in the bacterial 
cells. MSSA DMST 2933 bacterial cells became 
bloated and crushed after 4 h treatment. Also, 
some bacterial cells showed cavities and others 
were lysed (Figure 2B). Similar changes were 
observed following tetracycline treatment 
(concentration equal to 1 x MIC of the extract) 
(Figure 2C). Untreated control cells did not show 
any alterations in cell morphology (Figure 2A). In 
MRSA DMST 20651 treated with extract for 4 h, 
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some cells were bloated and crushed, cell 
surfaces were disrupted and broken, and some 
cells were lysed (Figure 2E). Similar 
morphological alterations occurred when MRSA 
was treated with tetracycline at a concentration 
of 1 x MIC (Figure 2F). Untreated MRSA cells did 
not appear damaged (Figure 2D). 
 
Anti-breast cancer cell activity 
 
The effects of various concentrations (1 - 500 
g/mL) of Streptomyces sp. SRF1 culture filtrate 
extract on the cell viability of breast cancer cell 
line MCF-7 were investigated using the SRB 
assay. High concentrations of extract reduced 
the viability of MCF-7 cells more than lower 
concentrations. Incubation time also directly 
affected cell viability compared with the control 
(Figure 3). The IC50 of the extract against MCF-7 
cells was 471.33 ± 52.82, 391.67 ± 20.58 and 
211.67 ± 33.95 g/mL for 24, 48 and 72 h, 
respectively. The highest Emax value, 71.53 ± 
5.13, was recorded at an exposure time of 72 h, 
followed by 48.91 ± 6.10 and 57.53 ± 5.41 for 24 
and 48 h, respectively. These results indicate 
that the extract exhibited concentration - and 
time - dependent cytotoxic activity against the 




Bacteria in the Streptomyces genus are well 
known to have bioactive secondary metabolite 
producing activity, these products widely used by 
the pharmaceutical industry for their 
antimicrobial, antiviral [20] and anticancer 
activities [9]. In previous studies, we 
demonstrated that Streptomyces sp. SRF1, 
isolated from a rice field, inhibits the growth of 
phytopathogenic fungi and the food-borne 
bacterial pathogen Bacillus cereus under in vitro 
conditions [14,15]. In the present work, the 
activity of this culture filtrate extract was 
investigated against other important bacterial 
strains and the breast cancer cell line MCF-7. 
The results demonstrate that the extract has 
activity against 4 strains of Staphylococcus 
aureus, but no activity against any of the test 
strains of Gram negative bacteria. These results 
may reflect the mode of antibacterial action of the 
extract. Because Gram negative and Gram 
positive bacteria differ in their cell wall structure, 
they have different characteristics in terms of 
available target site and molecule adsorption and 
uptake [21]. 
 
The results show that the pathogens MSSA 
DMST 2933, MRSA DMST 4738, MRSA DMST 
20651, and MRSA DMST 20654 were quite 
sensitive to the culture filtrate extract of 
Streptomyces sp. SRF1. Of these four strains, 
MRSA DMST 20651 had the highest resistance 
to ciprofloxacin and tetracycline antibiotics. Next, 
time - kill assays were performed with the culture 
filtrate extract on MRSA DMST 20651 and MSSA 
DMST 2933. These results indicate the culture 
filtrate extract is bactericidal, reducing viable cell 
counts of the tested S. aureus strains by more 
than 3 log10 in 6 h. Larger reductions in viable 
cell count (more than 10 log10) were observed 
when the extract concentration and exposure 
time were increased (Figure 1A and 1B). These 
results indicate that the culture filtrate extract kills 
S. aureus in both a concentration - and time - 




Figure 2: Scanning electron micrographs of S. aureus (MSSA) DMST 2933 (A - C) and S. aureus (MRSA) DMST 
20651 (D - F) after treatment with Streptomyces sp. SRF1 culture filtrate extract at 1 x MIC (0.195 mg/mL) (B and 
E), and the antibiotic tetracycline at 0.195 mg/mL (C and F) for 4 h as compared with untreated controls (A and 
D) 
Sangdee et al 




Figure 3: Effects of Streptomyces sp. SRF1 culture filtrate extract on the proliferation of breast cancer cell line 
MCF-7. MCF-7 cells were treated with various concentrations of 1 – 500 μg/mL for 24 - 72 h. The MCF-7 cell 
proliferation was measured by the SRB assay after treatment. The experiment was done in three independent 
experiments. The results are presented as percentage of control, and represent mean ± SEM values. *p < 0.05 
vs. untreated control groups 
 
opinion of Iniyan et al [22], who demonstrated 
that the phenolic compound T1 isolated from a 
marine-derived actinomycete Micromonospora 
sp. ICN36 inhibited the growth of MRSA and 
MSSA at low concentrations (MIC values of 0.5 
and 0.25 g/mL, respectively). Moreover, the 4 x 
MIC of the phenolic compound T1 showed 
bactericidal activity against MRSA after 4 h 
exposure [22]. 
 
To determine if the culture filtrate extract might 
exert its antibacterial activity by targeting the cell 
wall, we examined the effects of the extract on 
Staphylococcus aureus using SEM. At 1 x MIC, 
the extract altered the surface appearance and 
morphology of both MSSA and MRSA cells.  
Observed changes included cell bloating, a 
crushed appearance, cell surface disruption, and 
lysis. These cell alteration effects may be due to 
bioactive constituents in the culture filtrate extract 
disrupting peptidoglycan biosynthesis [23,24].  
Many bioactive compounds produced by 
Streptomyces spp., for example phenolic 
compounds and antibiotics, have been shown to 
alter cell surface appearance. Previous 
observations include wrinkling of the cell surface 
and cell shrinkage [22,24,25].   
 
Results from the anti-breast cancer assay clearly 
indicate that Streptomyces sp. SRF1 culture 
filtrate extract has concentration- and time-
dependent cytotoxic activity against the MCF-7 
cell line. This effect may be due to bioactive 
compounds present in the extract. Bioactive 
compounds isolated previously from 
Streptomyces spp. have been reported to inhibit 
the activation of survival signaling pathways in 
cancer cells [26,27]. Ser et al [11] demonstrated 
that a fermentation extract derived from S. 
pluripotens MUSC 137 had both significant 
antioxidant activity and significant cytotoxic 
activity.  Several cancer cell lines were shown to 
be susceptible including MCF-7. S. parvus 
extract has also been shown to be active against 
breast cancer cell lines [28]. Isolation and 
structure elucidation of the compounds 
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responsible for the bioactivities of Streptomyces 
sp. SRF1 culture filtrate extract are now 




The findings of this work show that Streptomyces 
sp. SRF1 culture filtrate extract has bactericidal 
activity against staphylococci bacteria including 
methicillin-resistant S. aureus. Furthermore, the 
extract also exerts activity against MCF-7 breast 
cancer cell line. Thus, Streptomyces sp. SRF1 
culture filtrate extract, after appropriate further 
investigation, may yield antibacterial and 
anticancer drug candidates. Further studies will 
now focus on isolating the compounds 
responsible for the observed bioactivities and 
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